Concepedia

LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2

S. Popat, K.L. Reckamp, Raffaele Califano, SH Lee, B. Melosky, J. Wang, Yuzhuo Wang, M.R. García Campelo, E. Felip, N. Girard,

Annals of Oncology · 2024 · 12 citations · 0 references

Open access

Concepts

MedicineOncologyPharmacologyChemotherapyMedical OncologyTumor ProgressionAdjuvant ChemotherapyCancer ProgressionLung CancerMalignant NeoplasmsTargeted Cancer TherapyTargeted TherapyEgfr DependenceEgfr InhibitionEgfr Mutation TestingEpidermal Growth Factor Receptor InhibitionErlotinib TherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer Treatment